UKUK

GSK and HGS get approval for lupus drug

15.07.2011

London/Rockville - GlaxoSmithKline and its American partner Human Genome Sciences, Inc. announced today that the European Commission has granted marketing authorisation for belimumab (Benlysta) as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus, with a high degree of disease activity (e.g. positive anti-dsDNA and low complement), despite standard therapy. "We and GSK are committed to making Benlysta available in countries worldwide," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "We are particularly honoured to be bringing this medicine forward in Europe, where a number of key academic research institutions were very important to its clinical development." Belimumab received approval from the U.S. FDA on March 9, 2011. GSK and HGS announced approval from Health Canada on July 12, 2011. Regulatory applications have been submitted and are currently under review in Australia, Switzerland, Russia, Brazil, The Philippines, Israel, Singapore, Taiwan and Colombia. HGS and GSK have been working together on belimumab since 2006. Under the agreement, HGS had responsibility for conducting the belimumab Phase 3 trials, with assistance from GSK. The companies share equally in Phase 3/4 development costs, sales and marketing expenses, and profits of any product commercialised under the current agreement.

UKUK

20.05.2008

London – The British government has launched a new Enterprise Strategy aimed at making the UK the “best place to start and grow a business”. The 10-year strategy has been produced jointly by the Treasury and the Department for...

UKUK

20.05.2008

London – “Chimera” embryos may increase pressure on the British parliament for tougher regulations on stem cell research. At the beginning of April, Dr. Lyle Armstrong and colleagues at Newcastle University created embryos from...

UKUK

26.03.2008

Syntaxin Ltd, a biopharmaceutical company developing novel biologic drugs that control cell secretion, has appointed Richard Jones, MD as Chief Medical Officer and Dr Nicola Thompson as Head of Cell Biology. Jones has over 25...

UKUK

26.03.2008

The very first biosimilar version of the human granulocyte colony stimulating factor (G-CSF), for the treatment of neutropenia, got the go-ahead from the European drug authority EMEA in February. The EMEA’s CHMP issued positive...

UK, Clinical TrialUK

25.03.2008

AIM-listed Verona Pharma’s (London) long-acting Phosphodiesterase 3 and 4 inhibitor RPL554 is going to enter clinical trials. After finalisation of an animal toxicological study of the nasally administered drug candidate for the...

UKUK

19.03.2008

London – Genotyping results from 1,600 patients who suffer from coeliac disease (gluten allergy) point to seven new risk loci for the condition. Six of these harbour genes implicated in the immune response (CCR3, IL12A, IL18RAP,...

UKUK

19.03.2008

London – Therapies based on genetic information are on the docket in the House of Lords, the upper chamber of the British parliament after its members started an inquiry into the state of this growing sector. The House of Lords...

UKUK

19.03.2008

Edinburgh – Scotland’s life sciences sector has been dealt a fresh blow after a cutting-edge stem-cell technology company decided to close its Edinburgh headquarters in favour of England. Stem Cell Sciences (SCS), which has...

UKUK

19.03.2008

London – Alistair Darling, Britain’s Chancellor of the Exchequer, has dissociated himself from his plans to relieve investors of capital gains tax. However, Darling did finally bow to business pressure – particularly from the...

UKUK

19.03.2008

Oxford – Partnering is one of the most important issues for biotech companies, and according to a recent Nature Biotech article (2007, Czerepak et. al.) pharma is becoming more and more dependent on innovations made in biotech....

Displaying results 181 to 190 out of 396

< Previous 181-190 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/18/article/gsk-and-hgs-get-approval-for-lupus-drug.html

Product of the week

Products

Events

All Events

Current issue

All issues